Latham & Watkins LLP represents the underwriters in the transaction. Silverback Therapeutics, Inc. (Silverback) announced the pricing of its initial public offering of 11,500,000 shares of…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
